Rheumatoid arthritis (RA) market
Oct 04, 2024
Fierce Competition Lies Ahead for Pipeline Therapies in the Rheumatoid Arthritis Market
The past decade experienced a lot of shuffling in the Rheumatoid arthritis market. The journey started with the approvals of disease-modifying anti-rheumatic drugs (DMARDs). Several conventional DMARDs constituting methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine, biologics with initial entrants bei...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
